Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Change in Acquisitions & Divestments for 15 consecutive years, with $267.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 6.74% year-over-year to $267.7 million, compared with a TTM value of $1.1 billion through Dec 2025, up 12.6%, and an annual FY2025 reading of $1.1 billion, up 12.6% over the prior year.
  • Change in Acquisitions & Divestments was $267.7 million for Q4 2025 at Neurocrine Biosciences, up from $225.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $298.6 million in Q2 2025 and bottomed at $161.3 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 4 years is $245.4 million, with a median of $265.3 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments fell 21.89% in 2021, then surged 70.53% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $161.3 million in 2021, then skyrocketed by 80.29% to $290.8 million in 2023, then decreased by 13.76% to $250.8 million in 2024, then grew by 6.74% to $267.7 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for NBIX at $267.7 million in Q4 2025, $225.0 million in Q3 2025, and $298.6 million in Q2 2025.